The Europe mRNA therapeutics market was valued at USD 4 billion in 2025 and is projected to reach USD 17.34 billion by 2035, expanding at a CAGR of 15.80% due to rising adoption of RNA-based therapies and increasing biopharmaceutical innovation.

Europe mRNA Therapeutics Market Statical Scope

Europe is growing significantly in the mRNA therapeutics industry. European companies such as CureVac and BioNTech (Germany), along with Etherna (Belgium), were pioneers in initiating clinical trials for mRNA-based solutions. The European Pharmacopoeia actively supports this growth by adopting new standards for mRNA vaccine production and quality control, which aim to streamline development processes and ensure the quality of mRNA-based products, thus reinforcing Europe's competitive position in the field.

Europe mRNA Therapeutics Market Share, By Application, 2025 (%)

• Infectious Diseases- Infectious diseases lead the segment, with a share of 38%, driven by strong use of mRNA platforms in vaccine development and rapid response to emerging viral threats.
• Oncology- Oncology holds a significant share of 32%, supported by growing adoption of mRNA-based immunotherapies and advancements in personalized cancer treatment.
• Rare Genetic Diseases- Rare genetic diseases account for a notable share of 12%, driven by increasing research into gene-based therapies and targeted molecular treatments.
• Respiratory Diseases- Respiratory diseases represent a share of 10%, supported by the ongoing development of mRNA solutions for influenza and other respiratory conditions.

Europe mRNA Therapeutics Market Share, By Type, 2025 (%)

• Prophylactic- Prophylactic leads the segment, with a share of 58%, driven by the strong dominance of mRNA vaccines designed for disease prevention and large-scale immunization programs.
• Therapeutic- Therapeutic accounts for a significant portion, with a share of 42%, supported by expanding research into mRNA-based treatments for chronic and rare diseases.

Europe mRNA Therapeutics Market Share, By End-use, 2025 (%)

• Hospitals & Clinics- Hospitals & clinics dominate the segment, with a share of 50%, driven by large-scale vaccine administration and clinical use of mRNA-based therapies.
• Research Organizations- Research organizations hold a strong share of 30%, supported by intensive R&D activities and continuous innovation in mRNA technology.
• Others- Others account for a share of 20%, driven by academic institutes, biotech firms, and emerging healthcare facilities engaged in mRNA development.

Top Companies in the Europe mRNA Therapeutics Market

• Moderna Inc.
• BioNTech SE
• CureVac N.V.
• Arcturus Therapeutics
• Sanofi
• GSK Plc.
• Argos Therapeutics Inc.
• Ethris
• Pfizer Inc.
• AstraZeneca

Segments Covered in the Report

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

By Type

• Prophylactic
• Therapeutic

By End-use

• Hospitals & Clinics
• Research Organizations
• Others